This company has been acquired
Pardes Biosciences Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Pardes Biosciences.
Key information
36.6%
Earnings growth rate
39.3%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 17 Jul 2023 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -34 | N/A | N/A | 1 |
12/31/2024 | N/A | -33 | N/A | N/A | 1 |
12/31/2023 | N/A | -77 | N/A | N/A | 1 |
6/30/2023 | N/A | -76 | -79 | -79 | N/A |
3/31/2023 | N/A | -93 | -78 | -78 | N/A |
12/31/2022 | N/A | -97 | -72 | -72 | N/A |
9/30/2022 | N/A | -87 | -76 | -76 | N/A |
6/30/2022 | N/A | -75 | -67 | -67 | N/A |
3/31/2022 | N/A | -55 | -54 | -54 | N/A |
12/31/2021 | N/A | -39 | -37 | -37 | N/A |
9/30/2021 | N/A | -36 | -23 | -23 | N/A |
6/30/2021 | N/A | -27 | -14 | -14 | N/A |
3/31/2021 | N/A | -20 | -8 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRDS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRDS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRDS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if PRDS's revenue is forecast to grow faster than the US market.
High Growth Revenue: PRDS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRDS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/09/01 05:35 |
End of Day Share Price | 2023/08/30 00:00 |
Earnings | 2023/06/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pardes Biosciences, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yuchen Ding | Jefferies LLC |
Douglas Buchanan | JMP Securities |
Roanna Clarissa Ruiz | Leerink Partners LLC |